Quote | Innate Pharma S.A. (NYSE:IPHA)
Last: | $ |
---|---|
Change Percent: | 1.60% |
Open: | $7.75 |
Close: | $7.60 |
High: | $7.75 |
Low: | $7.57 |
Volume: | 5,364 |
Last Trade Date Time: | 02/12/2020 04:44:19 pm |
News | Innate Pharma S.A. (NYSE:IPHA)
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
Message Board Posts | Innate Pharma S.A. (NYSE:IPHA)
Subject | By | Source | When |
---|---|---|---|
MomentumIts trading | lakoob2 | investorshub | 07/07/2023 2:27:48 PM |
Do we have a winner?Turn around time? | TheFinalCD | investorshub | 07/07/2023 5:16:31 AM |
$IPHA Good news recently, we should start to see this one move | tw0122 | investorshub | 07/05/2023 12:18:57 PM |
$IPHA short squeeze | crudeoil24 | investorshub | 07/05/2023 7:50:06 AM |
$IPHA where is the squeeze? | makinezmoney | investorshub | 07/03/2023 7:30:10 PM |
News, Short Squeeze, Breakout and More Instantly...
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi in R/R AML, B-ALL and HR-MDS SAR443579/IPH6101 continues ...